Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

310
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
310
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

367
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
367
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

662
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
662
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

422
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
422
Clearance Models: Physiological Models01:09

Clearance Models: Physiological Models

399
Drug clearance is a critical pharmacokinetic process involving the irreversible removal of drugs from the body through various organs over a specified time period. Physiological models are indispensable in determining organ-specific clearance, defined by the proportion of the drug eliminated per unit of time from the organ's blood volume.
The organ's clearance rate depends on the blood flow to the organ and the extraction ratio (E). The extraction ratio describes the organ's...
399
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

648
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
648

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ivermectin in veterinary medicine: a narrative review of antiparasitic efficacy, resistance evolution, antiviral evidence, and One Health implications.

Frontiers in veterinary science·2026
Same author

What Matters to Residential Long-Term Care Residents: Contextualizing Perceptions of Person-Centered Care.

Journal of the American Medical Directors Association·2026
Same author

Guided Ensemble Stacking Method for Predicting Biological Activities of Compounds.

Chemical biology & drug design·2025
Same author

Molecular simulations of paclitaxel binding to mutant β-tubulin: insights into chemotherapy resistance.

Journal of computer-aided molecular design·2025
Same author

Validity and reliability of the Resident VIEW (Voicing importance, experience, and well-being) and its short form.

The Gerontologist·2025
Same author

Delineating SARS-CoV-2 spike protein and antibodies interaction interfaces via siamese neural networks: A geometric and image-based analysis.

PloS one·2025

Related Experiment Video

Updated: Mar 14, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

13.2K

Building a 3D Virtual Liver: Methods for Simulating Blood Flow and Hepatic Clearance on 3D Structures.

Diana White1, Dennis Coombe2, Vahid Rezania3

  • 1Department of Mathematics, Clarkson University, Potsdam, New York, United States of America.

Plos One
|September 21, 2016
PubMed
Summary

This study introduces a novel computational model for simulating blood and drug flow within a 3D liver approximation. The method integrates fluid dynamics and drug metabolism (hepatic clearance) for comprehensive analysis.

More Related Videos

Visualization of Vascular and Parenchymal Regeneration after 70% Partial Hepatectomy in Normal Mice
11:10

Visualization of Vascular and Parenchymal Regeneration after 70% Partial Hepatectomy in Normal Mice

Published on: September 13, 2016

8.8K
In Vitro 3D Cell-Cultured Arterial Models for Studying Vascular Drug Targeting Under Flow
07:00

In Vitro 3D Cell-Cultured Arterial Models for Studying Vascular Drug Targeting Under Flow

Published on: March 14, 2021

3.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

13.2K
Visualization of Vascular and Parenchymal Regeneration after 70% Partial Hepatectomy in Normal Mice
11:10

Visualization of Vascular and Parenchymal Regeneration after 70% Partial Hepatectomy in Normal Mice

Published on: September 13, 2016

8.8K
In Vitro 3D Cell-Cultured Arterial Models for Studying Vascular Drug Targeting Under Flow
07:00

In Vitro 3D Cell-Cultured Arterial Models for Studying Vascular Drug Targeting Under Flow

Published on: March 14, 2021

3.7K

Area of Science:

  • Computational modeling
  • Liver physiology
  • Pharmacokinetics

Background:

  • Accurate simulation of liver processes is crucial for drug development.
  • Existing models often lack integration of vasculature and tissue dynamics.
  • A unified approach is needed for simulating blood flow and drug metabolism.

Purpose of the Study:

  • To develop a spatio-temporal modeling approach for liver blood and drug flow.
  • To simulate drug uptake and elimination within a 3D liver approximation.
  • To integrate fluid dynamics and hepatic clearance into a single computational framework.

Main Methods:

  • Generated a 3D liver approximation with portal and hepatic vasculature using constrained constructive optimization.
  • Converted vasculature to a spatial grid and assigned upscaled lobule tissue properties.
  • Simulated fluid flow and drug metabolism using discretized convective-diffusive-reactive partial differential equations.

Main Results:

  • Developed a consistent method for simulating blood and drug flow on a representative 3D liver structure.
  • Enabled simulation of drug metabolism (hepatic clearance) within the integrated model.
  • Provided a unified computational approach for studying liver drug dynamics.

Conclusions:

  • The developed spatio-temporal model offers a robust platform for in silico liver drug studies.
  • This approach enhances understanding of drug distribution and metabolism in the liver.
  • The method facilitates more accurate predictions of drug efficacy and toxicity.